Description of Research Expertise

The Bar Lab studies novel approaches to HIV prevention and cure. Our current research focuses on:
(i) characterizing the viral dynamics and host immune responses during virus suppression and treatment interruption,
(ii) developing NHP models that faithfully recapitulate HIV-1 latency and rebound, and
(iii) developing antibody-based interventions.

Selected Publications

Pahus MH, Zheng Y, Olefsky M, Gunst JD, Tebas P, Taiwo B, Søgaard OS, Peluso MJ, Lie Y, Reeves JD, Petropoulos CJ, Caskey M, Bar KJ.: Evaluation and real-world experience of a neutralization susceptibility screening assay for broadly neutralizing anti-HIV-1 antibodies. J Infect Dis doi: 10.1093/infdis/jiae486 : 2024.

Mainou E, Berendam SJ, Obregon-Perko V, Uffman EA, Phan CT, Shaw GM, Bar KJ, Kumar MR, Fray EJ, Siliciano JM, Siliciano RF, Silvestri G, Permar SR, Fouda GG, McCarthy J, Chahroudi A, Conway JM, Chan C.: Assessing the impact of autologous virus neutralizing antibodies on viral rebound time in postnatally SHIV-infected ART-treated infant rhesus macaques. Epidemics 48 (100780): 2024.

Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, Riley JL: CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication J Clin Invest 134 (9): e181576,2024.

Whitehill GD, Joy J, Marino FE, Krause R, Mallick S, Courtney H, Park K, Carey J, Hoh R, Hartig H, Pae V, Sarvadhavabhatla S, Donaire S, Deeks SG, Lynch RM, Lee SA, Bar KJ: Autologous neutralizing antibody responses after antiretroviral therapy in acute and early HIV-1 J Clin Invest 134 (11): 2024.

Miner MD, deCamp A, Grunenberg N, De Rosa SC, Fiore-Gartland A, Bar K, Spearman P, Allen M, Yu PC, Manso B, Frahm N, Kalams S, Baden L, Keefer MC, Scott HM, Novak R, Van Tieu H, Tomaras GD, Kublin JG, McElrath MJ, Corey L, Frank I; HVTN 085 Study Team: Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial EBioMedicine 100 : 104987,2024.

Maurine D. Miner, Allan deCamp, Nicole Grunenberg, Stephen C. De Rosa, Andrew Fiore-Gartland, Katherine Bar, Paul Spearman, Mary Allen, Pei-Chun Yu, Bryce Manso, Nicole Frahm, Spyros Kalams, Lindsey Baden, Michael C. Keefer, Hyman M. Scott, Richard Novak, Hong Van Tieu, Georgia D. Tomaras, James G. Kublin, M. Juliana McElrath, Lawrence Corey, Ian Frank, Artur Kalichman, Paul Edlefsen, Mary Enama, John Hural, Renee Holt, Debora Dunbar, Dave Crawford, Ian Maki, Jan Johannessen, Scharla Estep, Yevgeny Grigoriev, Tamra Madenwald, Marianne Hansen, Drienna Holman, Ramey Fair, Genevieve Meyer, Anya Luke-Kilolam: Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial. eBioMedicine 100 : 2024.

Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen P, Morris L, Mkhize NN, Williamson C, Mullins JI, Seaton KE, Tomaras GD, Andrew P, Mgodi N, Ledgerwood JE, Cohen MS, Corey L, Naidoo L, Orrell C, Goepfert PA, Casapia M, Sobieszczyk ME, Karuna ST, Edupuganti S.: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nat Commun 14 (1): 8299,2023.

Docken SS, McCormick K, Pampena MB, Samer S, Lindemuth E, Pinkevych M, Viox EG, Wu Y, Schlub TE, Cromer D, Keele BF, Paiardini M, Betts MR, Bar KJ, Davenport MP.: Preferential selection of viral escape mutants by CD8+ T cell 'sieving' of SIV reactivation from latency. PLoS Pathog 19 (11): e1011755,2023.

Tieu HV, Karuna S, Huang Y, Sobieszczyk ME, Zheng H, Tomaras GD, Montefiori DC, Shen M, DeRosa S, Cohen K, Isaacs MB, Regenold S, Heptinstall J, Seaton KE, Sawant S, Furch B, Pensiero M, Corey L, Bar KJ; HVTN 122 Study Team: Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US. Vaccine 41 (42): 6309-6317,2023.

Podgorski RM, Robinson JA, Smith MD, Mallick S, Zhao H, Veazey RS, Kolson DL, Bar KJ, Burdo TH: Transmitted/founder SHIV.D replicates in the brain, causes neuropathogenesis, and persists on combination antiretroviral therapy in rhesus macaques Retrovirology 20 (1): 13,2023.

Academic Contact Information

502 D Johnson Pavilion
3610 Hamilton Walk

Philadelphia, PA 19104-6073
Phone: 215-573-8497
Patient appointments: 800-789-7366